Combination antidepressants are not yet proven therapy in the treatment of depression

References

• Horgan D, Dodd S, Berk M. A survey of combination antidepressant use in Australia. Australasian Psychiatry 2007; 15: 26–29
   PubMed Web of Science ®Google Scholar
• Aguera LF, Rojo JE, de la Gandara J, ii. Antidepressant combinations: Epidemiological considerations. Acta Psychiatrica Scandinavica 2005; 112(Suppl. 428)7–10
   Google Scholar
• Freedman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. Journal of Clinical Psychiatry 2000; 61: 403–408
   PubMed Web of Science ®Google Scholar
• McManus P, Mant A, Mitchell P, et al. Co-prescription of SSRIs and TCAs in Australia: how often does it occur and who is doing it?. British Journal of Clinical Pharmacology 2001; 51: 93–98
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: A systemic review. Journal of Clinical Psychiatry 2006; 67: 1836–1855
   PubMed Web of Science ®Google Scholar
• Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. Journal of Clinical Psychopharmacology 1999; 19: 427–434
   PubMed Web of Science ®Google Scholar
• Jackson IM. Does thyroid hormone have a role as adjunctive therapy in depression?. Thyroid 1996; 6: 63–67
   PubMed Web of Science ®Google Scholar
• Dodd S, Horgan D, Malhi GS, et al. To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders 2005; 89: 1–11
   PubMed Web of Science ®Google Scholar
• Davidson J, McLeod M, Law-Yone B, et al. A comparison of electrovconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Archives of General Psychiatry 1978; 35: 639–642
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. American Journal of Psychiatry 1994; 151: 1372–1374
   PubMed Web of Science ®Google Scholar
• Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and non-responders to fluoxetine. Journal of Clinical Psychopharmacology 2002; 22: 379–387
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomised study. Biological Psychiatry 2004; 55: 296–300
   PubMed Web of Science ®Google Scholar
• Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. Psychopharmacology 2002; 161: 143–151
   PubMed Web of Science ®Google Scholar
• Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatrica Scandinavica 2001; 103: 66–72
   PubMed Web of Science ®Google Scholar
• Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalised major depressed patients, including those with treatment resistance. Journal of Clinical Psychopharmacology 1999; 19: 177–182
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry 2002; 51: 183–188.
   PubMed Web of Science ®Google Scholar
• Young JPR, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. British Medical Journal 1979; 2: 1315–1317
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatric Clinics of North America 2003; 26: 457–494
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Buproprion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 2006; 354: 1231–1242
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 2006; 354: 1243–1252
   PubMed Web of Science ®Google Scholar